Two pioneers. One mission: To revolutionize antibody characterization by turning a manual art into a high-speed, scalable industrial pipeline.
Our standard 96-well format RaPiD-mAb-MS™ reagent kits are compatible with both bench pipetting and automated liquid handlers. They include digestion enzymes and proprietary chemistry that seamlessly remove excipients, sugars, and surfactants, eliminating the need for tedious desalting steps. Best of all, every kit purchase includes the RaPiD-Analyze™ software needed for comprehensive data analysis – no additional costs or licenses.
From the Genome to the Proteome
CeleramAb is the result of a unique partnership between two generations of biotechnology innovators at the University of Wisconsin-Madison.
Forty years ago, Professor Lloyd Smith revolutionized biology by automating the manual process of DNA sequencing, creating the instruments that sequenced the human genome and launching a global industry. Today, Professor Joshua Coon is applying those same principles of speed, automation, and simplicity to the modern bottleneck of protein analysis.
Operating under an exclusive license agreement with the Wisconsin Alumni Research Foundation (WARF), they founded CeleramAb to do for peptide mapping what the sequencer did for DNA: Turn a manual art into a high-speed industrial science.
Company Profile
Company: CeleramAb Inc. (Pronounced: se-lehr-a-mab)
Origins of the name: CeleramAb is derived from the fusion of the Latin word celeritas (meaning swiftness or speed) and mAb (monoclonal antibody). The name reflects our foundational mission: bringing unprecedented speed to biotherapeutic analysis.
Founded: October 2024
Location: Madison, Wisconsin
Intellectual Property: Secured global, exclusive commercial rights across all foundational and applied patent families from the Wisconsin Alumni Research Foundation (WARF).
Co-Founder & Inventor
Joshua J. Coon, Ph.D.
Professor Coon is the Thomas & Margaret Pyle Chair at the Morgridge Institute for Research and a Professor at the University of Wisconsin-Madison. A globally recognized innovator, his lab is a powerhouse of translational science, specializing in technologies that fundamentally reshape proteomics.
Co-Invented Electron Transfer Dissociation (ETD)
A revolution in peptide sequencing now standard on over 1,500 mass spectrometers globally.
Invented Parallel Reaction Monitoring (PRM)
A targeted proteomics method that has become a staple for high-precision quantification.
Metrics of Innovation
Over 400 Peer-Reviewed Publications (approx. 40,000 citations), over 50 Issued and Pending Patents.
I have spent 20 years building the tools that drive modern proteomics. With CeleramAb, we are solving the final bottleneck—speed—to turn peptide mapping from a 60-minute chore into a 1-minute science.
Co-Founder & Strategic Director
Lloyd M. Smith, Ph.D.
Professor Smith is a serial entrepreneur and the W.L. Hubbell Professor of Chemistry at the University of Wisconsin-Madison. A pioneer in the automation of biology, his career is defined by transforming manual laboratory processes into scalable, multi-million-dollar industries.
A History of Commercial Success
Co-founded Third Wave Technologies in 1993, guiding it to a successful IPO in 2001 and eventual acquisition by Hologic for $580 million in 2008.
Inventor of Automated DNA Sequencing
Co-invented the fluorescence-based automated DNA sequencer, the technological foundation for sequencing the human genome.
Metrics of Innovation
Over 340 Peer-Reviewed Publications (approx. 37,000 citations), over 40 Issued U.S. Patents.
In the 1980s, we automated DNA sequencing to unlock the genome. Today, with CeleramAb, we are applying those same principles of speed and automation to the proteome.
